Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.48 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.47 |
| ▸ | DPP3 | Q9NY33 | 3/20 | 0.46 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517373 | 1.00 | CXCR4 (0.48) | CXCR4PCSK9DPP3IL23RF13A1 | |
| SCHEMBL31130668 | 0.94 | CXCR4 (0.48) | CXCR4PCSK9DPP3IL23RF13A1 | |
| SCHEMBL30517370 | 0.90 | PCSK9 (0.47) | CXCR4PCSK9IL23RCCKBRKISS1R | |
| SCHEMBL30517374 | 0.90 | PCSK9 (0.46) | CXCR4PCSK9IL23RF13A1TGM2 | |
| SCHEMBL30517411 | 0.90 | CXCR4 (0.48) | CXCR4DPP3IL23RF13A1TGM2 | |
| SCHEMBL29366452 | 0.87 | PCSK9 (0.52) | PCSK9IL23RCCKBR | |
| SCHEMBL30517383 | 0.87 | IL23R (0.47) | CXCR4PCSK9IL23RCCKBRKISS1R | |
| SCHEMBL30517393 | 0.86 | CCKBR (0.46) | CXCR4PCSK9IL23RCCKBR | |
| SCHEMBL30517378 | 0.83 | PCSK9 (0.45) | CXCR4PCSK9IL23RCCKBRKISS1R | |
| SCHEMBL30517386 | 0.83 | CXCR4 (0.48) | CXCR4DPP3IL23RF13A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250281634-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | TUBULIS GMBH (DE) | 2025-09-11 | — | — | US | disclosed |
| US-20240342296-A1 | pH LOW INSERTION PEPTIDE TARGETED DELIVERY OF POTENT CYTOTOXIC COMPOUNDS | YALE UNIVERSITY | 2024-10-17 | — | — | US | disclosed |
| US-12029793-B2 | pH low insertion peptide targeted delivery of potent cytotoxic compounds | YALE UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118302197-A | Conjugates comprising phosphorus (V) and a drug moiety | TUBULIS 股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024133845-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| US-20230330258-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | TUBULIS GMBH (DE) | 2023-10-19 | — | — | US | disclosed |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-23 | — | — | US | disclosed |
| CN-114158253-A | pHLIP targeted delivery of potent cytotoxic compounds | 罗德岛大学理事会 | 2022-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342296-A1 | pH LOW INSERTION PEPTIDE TARGETED DELIVERY OF POTENT CYTOTOXIC COMPOUNDS | PMAIP1, SCAMP2, CHERP | CXCR4 1593/4885PCSK9 1898/4885DPP3 2350/4885 |
| US-20250281634-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | CALCR, BCR, PTH1R | CXCR4 143/4885PCSK9 1094/4885DPP3 1691/4885 |
| US-20230330258-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | CALCR, BCR, PTH1R | CXCR4 143/4885PCSK9 1094/4885DPP3 1691/4885 |
| US-12029793-B2 | pH low insertion peptide targeted delivery of potent cytotoxic compounds | SLC7A1, SLC47A1, VIP | CXCR4 1204/4885PCSK9 1147/4885DPP3 1530/4885 |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | TUBB6, GALNT10, TUBB | CXCR4 2923/4885PCSK9 3846/4885DPP3 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.